| Gene symbol | F | Synonyms | None | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_001803.1 (5619..7521) | dbXrefs | |
| Description | Fusion protein (F) | ||||
| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| GTO ID | GTC3212 |
| Trial ID | NCT05585632 |
| Disease | Respiratory Syncytial Virus Infectious Disease | Influenza | COVID-19 |
| Altered gene | F|S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | mRNA-1045;mRNA-1230;mRNA-1010 |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age |
| Year | 2022 |
| Country | Australia|United Kingdom|United States |
| Company sponsor | ModernaTX, Inc. |
| Other ID(s) | mRNA-1230-P101|2022-002138-15 |
| Vector information | |||
|
|||
| Cohort1: mRNA-1010 | |||||||
|
|||||||
| Cohort2: mRNA-1345 | |||||||
|
|||||||
| Cohort3: mRNA-1273.214 | |||||||
|
|||||||
| Cohort4: mRNA-1045 | |||||||
|
|||||||
| Cohort5: mRNA-1230 | |||||||
|
|||||||